UBERON:0002346

Name:	neurectoderm
Namespace:	FANTOM
Definition:	"Embryonic ectoderm that gives rise to nervous tissue." [Wikipedia:Neuroectoderm]
Xrefs:	Expandlinks: AAO:0011074 BILA:0000039 EHDAA2:0001248 EHDAA:1498 EHDAA:255 EMAPA:16073 EV:0100004 FBbt:00001061 FMA:87657 MAT:0000176 MIAA:0000176 ncithesaurus:Neuroectoderm TAO:0001120 VHOG:0000150 XAO:0000042 ZFA:0001120
Synonyms:	"epithelium tubi neuralis; neuroectoderma" RELATED LATIN [Wikipedia:Neuroectoderm] "neuaral ectoderm" RELATED [] "neural ectoderm" EXACT [] "neuroectoderm" EXACT [] "presumptive central nervous system" RELATED []
Comments:	Terminology notes: we prefer neurectoderm to neural ectoderm since placodal ectoderm is not classified here
Alt_id:	UBERON:FMA_87657-MIAA_0000176-XAO_0000042-ZFA_0001120
Subset:	uberon_slim vertebrate_core

Ontology association<br>Each term has an is_a parent in the Uberon Ontology, which has a linkage to an another entity and FANTOM5 samples.Libraries were grouped into mutually exclusive facets according to the FANTOM5 sample ontology mapping to UBERON ontologies.<br><br>link to ontology dataset<br>data

---

Parents

is_a:	UBERON:0000923(germ layer),UBERON:0004121(ectoderm-derived structure)
develops_from:	UBERON:0000924(ectoderm)

Children

is a:	FF:10637-108I7 (neuroectodermal tumor cell line:FU-RPNT-1),FF:10663-109C6 (neuroectodermal tumor cell line:FU-RPNT-2),FF:10697-109G4 (peripheral neuroectodermal tumor cell line:KU-SN),FF:10774-110F9 (neuroectodermal tumor cell line:TASK1)
develops from:	UBERON:0001775 (ciliary body),UBERON:0003050 (olfactory placode),UBERON:0003075 (neural plate),UBERON:0004128 (optic vesicle),UBERON:0007284 (presumptive neural plate)
part of:	UBERON:0002342 (neural crest),UBERON:0003075 (neural plate),UBERON:0006238 (future brain)

Ontology Tree: Loaded from BioPortal

Ontorolgy tree(Small window open)

FF samples<br>It includes FANTOM5 samples that overlay the Uberon ontology

---

Human (Homo sapiens)

• 10637-108I7 (neuroectodermal tumor cell line:FU-RPNT-1)
• 10663-109C6 (neuroectodermal tumor cell line:FU-RPNT-2)
• 10697-109G4 (peripheral neuroectodermal tumor cell line:KU-SN)
• 10774-110F9 (neuroectodermal tumor cell line:TASK1)

Enrichment analysis: top 100 FFCP enriched with this ontology term TOP 100 FANTOM5 Cage Peaks enriched with UBERON:0002346 (neurectoderm), sorted by p-values <br>Analyst: Hideya Kawaji<br><br>link to source dataset <br>human : data <br>mouse : data

---

Copy Excel CSV PDF

Search:

P-value	FFCP	Short description

P-value	FFCP	Short description
4.32e-103	FFCP PHASE2:Hg19::chr5:11588907..11588967,-	p3@CTNND2
4.32e-103	FFCP PHASE1:Hg19::chr5:11588907..11588967,-	p3@CTNND2
2.11e-102	FFCP PHASE2:Hg19::chr11:31839488..31839515,-	p3@PAX6
2.11e-102	FFCP PHASE1:Hg19::chr11:31839488..31839515,-	p3@PAX6
1.77e-98	FFCP PHASE2:Hg19::chr17:54230819..54230848,+	p1@ANKFN1
1.77e-98	FFCP PHASE1:Hg19::chr17:54230819..54230848,+	p1@ANKFN1
2.49e-97	FFCP PHASE2:Hg19::chr4:165305086..165305179,-	p2@MARCH1
2.49e-97	FFCP PHASE1:Hg19::chr4:165305086..165305179,-	p2@MARCH1
2.85e-95	FFCP PHASE1:Hg19::chr2:74612644..74612670,+	p1@ENST00000412957
2.85e-95	FFCP PHASE2:Hg19::chr2:74612644..74612670,+	p1@ENST00000412957
3.65e-95	FFCP PHASE2:Hg19::chr5:87439352..87439386,-	p@chr5:87439352..87439386, -
3.65e-95	FFCP PHASE1:Hg19::chr5:87439352..87439386,-	p@chr5:87439352..87439386, -
1.65e-94	FFCP PHASE1:Hg19::chr5:87980761..87980821,-	p4@LINC00461
1.65e-94	FFCP PHASE2:Hg19::chr5:87980761..87980821,-	p4@LINC00461
1.56e-93	FFCP PHASE2:Hg19::chr5:11384884..11384916,-	p8@CTNND2
1.56e-93	FFCP PHASE1:Hg19::chr5:11384884..11384916,-	p8@CTNND2
1.77e-93	FFCP PHASE1:Hg19::chr12:106976678..106976708,+	p2@RFX4
1.77e-93	FFCP PHASE2:Hg19::chr12:106976678..106976708,+	p2@RFX4
2.16e-93	FFCP PHASE1:Hg19::chr2:50201220..50201261,-	p3@NRXN1
2.16e-93	FFCP PHASE2:Hg19::chr2:50201220..50201261,-	p3@NRXN1
3.46e-93	FFCP PHASE2:Hg19::chr9:19789059..19789070,-	p2@SLC24A2
3.46e-93	FFCP PHASE1:Hg19::chr9:19789059..19789070,-	p2@SLC24A2
4.22e-93	FFCP PHASE1:Hg19::chr18:32398296..32398318,+	p7@DTNA
4.22e-93	FFCP PHASE2:Hg19::chr18:32398296..32398318,+	p7@DTNA
6.23e-93	FFCP PHASE2:Hg19::chr8:18541544..18541592,-	p2@PSD3
6.23e-93	FFCP PHASE1:Hg19::chr8:18541544..18541592,-	p2@PSD3
1.56e-92	FFCP PHASE2:Hg19::chr11:62475005..62475041,-	p6@BSCL2
1.56e-92	FFCP PHASE1:Hg19::chr11:62475005..62475041,-	p6@BSCL2
2.16e-92	FFCP PHASE1:Hg19::chr5:146314142..146314146,-	p@chr5:146314142..146314146, -
2.16e-92	FFCP PHASE2:Hg19::chr5:146314142..146314146,-	p@chr5:146314142..146314146, -
4.94e-92	FFCP PHASE1:Hg19::chr12:20848486..20848542,+	p1@SLCO1C1
4.94e-92	FFCP PHASE2:Hg19::chr12:20848486..20848542,+	p1@SLCO1C1
9.18e-92	FFCP PHASE2:Hg19::chrX:139803820..139803865,+	p@chrX:139803820..139803865, +
9.18e-92	FFCP PHASE1:Hg19::chrX:139803820..139803865,+	p@chrX:139803820..139803865, +
1.02e-91	FFCP PHASE2:Hg19::chr17:36760961..36760976,-	p2@SRCIN1
1.02e-91	FFCP PHASE1:Hg19::chr17:36760961..36760976,-	p2@SRCIN1
1.19e-91	FFCP PHASE2:Hg19::chr4:46126009..46126045,-	p1@GABRG1
1.19e-91	FFCP PHASE1:Hg19::chr4:46126009..46126045,-	p1@GABRG1
2.32e-91	FFCP PHASE1:Hg19::chr19:30016395..30016433,+	p@chr19:30016395..30016433, +
2.32e-91	FFCP PHASE2:Hg19::chr19:30016395..30016433,+	p@chr19:30016395..30016433, +
3.27e-91	FFCP PHASE1:Hg19::chr5:11386115..11386130,-	p2@CTNND2
3.27e-91	FFCP PHASE2:Hg19::chr5:11386115..11386130,-	p2@CTNND2
5.78e-91	FFCP PHASE1:Hg19::chr15:46702499..46702523,+	p@chr15:46702499..46702523, +
5.78e-91	FFCP PHASE2:Hg19::chr15:46702499..46702523,+	p@chr15:46702499..46702523, +
6.2e-91	FFCP PHASE1:Hg19::chr12:106976656..106976672,+	p4@RFX4
6.2e-91	FFCP PHASE2:Hg19::chr12:106976656..106976672,+	p4@RFX4
6.65e-91	FFCP PHASE1:Hg19::chr1:84630574..84630602,+	p9@PRKACB
6.65e-91	FFCP PHASE2:Hg19::chr1:84630574..84630602,+	p9@PRKACB
9.73e-91	FFCP PHASE2:Hg19::chrX:13835398..13835429,-	p6@GPM6B
9.73e-91	FFCP PHASE1:Hg19::chrX:13835398..13835429,-	p6@GPM6B
9.99e-91	FFCP PHASE1:Hg19::chr1:84630610..84630621,+	p17@PRKACB
9.99e-91	FFCP PHASE2:Hg19::chr1:84630610..84630621,+	p17@PRKACB
1.35e-90	FFCP PHASE2:Hg19::chr6:136848260..136848296,-	p4@MAP7
1.35e-90	FFCP PHASE1:Hg19::chr6:136848260..136848296,-	p4@MAP7
1.57e-90	FFCP PHASE1:Hg19::chr16:4850844..4850888,-	p@chr16:4850844..4850888, -
1.57e-90	FFCP PHASE2:Hg19::chr16:4850844..4850888,-	p@chr16:4850844..4850888, -
2.14e-90	FFCP PHASE2:Hg19::chr10:62149542..62149590,-	p1@ANK3
2.14e-90	FFCP PHASE1:Hg19::chr10:62149542..62149590,-	p1@ANK3
2.39e-90	FFCP PHASE1:Hg19::chr9:87283501..87283520,+	p17@NTRK2
2.39e-90	FFCP PHASE2:Hg19::chr9:87283501..87283520,+	p17@NTRK2
2.61e-90	FFCP PHASE2:Hg19::chr1:2005182..2005194,+	p8@PRKCZ
2.61e-90	FFCP PHASE1:Hg19::chr1:2005182..2005194,+	p8@PRKCZ
4.63e-90	FFCP PHASE1:Hg19::chr6:80131670..80131724,+	p@chr6:80131670..80131724, +
4.63e-90	FFCP PHASE2:Hg19::chr6:80131670..80131724,+	p@chr6:80131670..80131724, +
4.84e-90	FFCP PHASE2:Hg19::chr12:106976774..106976788,+	p1@RFX4
4.84e-90	FFCP PHASE1:Hg19::chr12:106976774..106976788,+	p1@RFX4
5.68e-90	FFCP PHASE2:Hg19::chr13:25746318..25746350,-	p3@FAM123A
5.68e-90	FFCP PHASE1:Hg19::chr13:25746318..25746350,-	p3@FAM123A
7.47e-90	FFCP PHASE1:Hg19::chr5:160279207..160279247,-	p1@ATP10B
7.47e-90	FFCP PHASE2:Hg19::chr5:160279207..160279247,-	p1@ATP10B
8.65e-90	FFCP PHASE1:Hg19::chr4:46126063..46126087,-	p2@GABRG1
8.65e-90	FFCP PHASE2:Hg19::chr4:46126063..46126087,-	p2@GABRG1
8.97e-90	FFCP PHASE1:Hg19::chr16:76311254..76311274,+	p2@CNTNAP4
8.97e-90	FFCP PHASE2:Hg19::chr16:76311254..76311274,+	p2@CNTNAP4
2.17e-89	FFCP PHASE2:Hg19::chr7:47420733..47420758,-	p@chr7:47420733..47420758, -
2.17e-89	FFCP PHASE1:Hg19::chr7:47420733..47420758,-	p@chr7:47420733..47420758, -
2.55e-89	FFCP PHASE1:Hg19::chrX:13835312..13835321,-	p9@GPM6B
2.55e-89	FFCP PHASE2:Hg19::chrX:13835312..13835321,-	p9@GPM6B
2.57e-89	FFCP PHASE1:Hg19::chr5:112074041..112074101,+	p4@APC
2.57e-89	FFCP PHASE2:Hg19::chr5:112074041..112074101,+	p4@APC
2.87e-89	FFCP PHASE2:Hg19::chr2:74612614..74612643,+	p1@ENST00000418990, p1@ENST00000426715, p1@ENST00000427343
2.87e-89	FFCP PHASE1:Hg19::chr2:74612614..74612643,+	p1@ENST00000418990, p1@ENST00000426715, p1@ENST00000427343
7.17e-89	FFCP PHASE1:Hg19::chr18:32398400..32398416,+	p10@DTNA
7.17e-89	FFCP PHASE2:Hg19::chr18:32398400..32398416,+	p10@DTNA
8.04e-89	FFCP PHASE1:Hg19::chr17:68101117..68101162,+	p2@KCNJ16
8.04e-89	FFCP PHASE2:Hg19::chr17:68101117..68101162,+	p2@KCNJ16
8.72e-89	FFCP PHASE1:Hg19::chr18:32398372..32398394,+	p5@DTNA
8.72e-89	FFCP PHASE2:Hg19::chr18:32398372..32398394,+	p5@DTNA
9.14e-89	FFCP PHASE1:Hg19::chr17:42989121..42989166,-	p7@GFAP
9.14e-89	FFCP PHASE2:Hg19::chr17:42989121..42989166,-	p7@GFAP
2.05e-88	FFCP PHASE1:Hg19::chr6:56716896..56716928,-	p8@DST
2.05e-88	FFCP PHASE2:Hg19::chr6:56716896..56716928,-	p8@DST
2.12e-88	FFCP PHASE1:Hg19::chr5:11384929..11384947,-	p15@CTNND2
2.12e-88	FFCP PHASE2:Hg19::chr5:11384929..11384947,-	p15@CTNND2
2.37e-88	FFCP PHASE2:Hg19::chr10:25940658..25940700,+	p1@ENST00000450270
2.37e-88	FFCP PHASE1:Hg19::chr10:25940658..25940700,+	p1@ENST00000450270
2.7e-88	FFCP PHASE1:Hg19::chr17:7558857..7558903,+	p@chr17:7558857..7558903, +
2.7e-88	FFCP PHASE2:Hg19::chr17:7558857..7558903,+	p@chr17:7558857..7558903, +
2.76e-88	FFCP PHASE2:Hg19::chr15:30261066..30261096,-	p12@TJP1
2.76e-88	FFCP PHASE1:Hg19::chr15:30261066..30261096,-	p12@TJP1

Showing 1 to 100 of 100 entries